869881-54-9

Briobacept (BR 3FC) is a recombinant glucoprotein, consists of 2 molecules from the BLyS receptor (BR3)and a Fc domain of human IgG1. Briobacept selectively targets to BLyS (BAFF), induces B cells apoptosis. Briobacept can be used in studies of rheumatoid arthritis (RA)[1][2].

[1] Sifuentes Giraldo WA, et al. New targets in systemic lupus (part 2/2). Reumatol Clin. 2012 Sep-Oct;8(5):263-9. DOI:10.1016/j.reuma.2012.01.013
[2] Liu Yunjie, et al. Research progress on the pathogenesis and drug targeting therapy of B lymphocyte stimulator-induced rheumatoid arthritis. 2011;22(33):3152-3154.
[3] La Cava A. Targeting B cells with biologics in systemic lupus erythematosus. Expert Opin Biol Ther. 2010 Nov;10(11):1555-61. DOI:10.1517/14712598.2010.524923
[4] Kayagaki N, et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity. 2002 Oct;17(4):515-24. DOI:10.1016/s1074-7613(02)00425-9